Patent details

LUC00176 Product Name: Saxagliptine et dapagliflozine

Basic Information

Publication number:
LUC00176
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP087326955
Legal Status:
Inactive
Application number:
LUC00176
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/16/1108
Marketing Authorization Type:
Marketing Authorization Date:
19/07/2016
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
31/08/2020
First Marketing Authorization date:
19/07/2016
Grant date:
29/04/2022
Activation date:
Publication date:
03/09/2020
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
19/07/2031
SPC Extension Expiration:
19/07/2031
Rejection date:
Withdrawal date:

Owner

From:
31/08/2020
 
 

Name:
AstraZeneca AB
Address:
Forskargatan 18, 151 85 Södertälje, Sweden (SE)

Agent

Name:
MARKS & CLERK LLP
From:
31/08/2020
Address:
BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2020/11
Publication date:
02/10/2020
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2022/06
Publication date:
03/05/2022
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/03/2028
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
31/08/2020 General Document 2
31/08/2020 General Document 43
31/08/2020 Application Form 4
31/08/2020 Incoming Correspondence (Post) 1
03/09/2020 Outgoing Correspondence 1
31/08/2020 General Document 3
31/08/2020 General Document 9
29/04/2022 Publication 1
03/09/2020 Publication 1
29/04/2022 Certificate 1
02/05/2022 Outgoing Correspondence 1
12/08/2022 Request For Change 1
02/09/2022 Outgoing Correspondence 56